This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview

This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

Optimizing Antibiotic Therapy to Treat Gram-negative Pathogens and Improve Outcomes in HAP/VAP

Optimizing Antibiotic Therapy to Treat Gram-negative Pathogens and Improve Outcomes in HAP/VAP

Format

Patient Case Study

Time to Complete

30 minutes

Released

June 28, 2019

Expires

June 28, 2020
Add to Queue


Maximum Credits

0.50 / AMA PRA Category 1 CreditTM
0.50 / CE for Pharmacists (0.05 CEU)
0.10 / IACET CEU

Accredited Provider



Sponsored by Academy for Continued Healthcare Learning

Commercial Supporter

Supported by an educational grant from Merck & Company.

Program Description

The purpose of this activity is to provide clinicians who care for patients with serious infections with the latest data on antimicrobial stewardship, available and emerging antibiotics against Gram-negative pathogens, and the optimization of therapy to improve outcomes and reduce resistance.

Agenda

I. VAP/HAP: Case Presentation
II. Challenges with P. aeruginosa
III. Ensuring Effectiveness of Antibiotics and Reducing Resistance
IV. New and Emerging Approaches to Gram-negative Organisms
V. Antimicrobial Susceptibility Testing
VI. Molecular Epidemiology of Antibiotic Resistance
VII. cUTIs: Case Presentation and Panel Discussion

Intended Audience

This activity is intended for ID specialists, hospitalists, pharmacists and other healthcare professionals who care for patients with serious infections.

Educational Objectives

Upon proper completion of this activity, participants should be better able to:

  • Summarize the burden of HAP/VAP and challenges associated with its management
  • Outline patient and clinical factors that increase risks for resistant Gram-negative pathogens
  • Describe strategies to optimize antimicrobial therapy to ensure effectiveness and reduce resistance

Conflict of Interest Disclosure Policy

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME/CE/CPE activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME/CE/CPE activity.

Faculty

George H. Karam, MD
Paula Garvey Manship Chair of Medicine
Head of the LSUHSC Dept. of Internal Medicine
Louisiana State University
Baton Rouge, LA

Dr. Karam discloses the following:
Advisory Board: Merck, Paratek, and Shionogi
Consultant: Shionogi and Tetraphase
Honoraria Recipient: Merck

James Lewis, II, PharmD, FIDSA
Infectious Disease Clinical Pharmacy Supervisor
Co-Director of Antibiotic Stewardship
Department of Pharmacy
Oregon Health & Science University
Portland, OR

Dr. Lewis discloses the following:
Consultant: Merck and Tetraphase

Jason M. Pogue, PharmD, BCPS‐ID
Clinical Pharmacist, Infectious Diseases
Sinai‐Grace Hospital
Detroit Medical Center
Clinical Assistant Professor of Medicine
Wayne State University School of Medicine
Detroit, MI

Dr. Pogue discloses the following:
Consultant: Melinta, Merck, Nabriva, Shionogi, and Tetraphase
Speakers Bureau: Melinta and Merck
Grant Support: Merck

Patricia (Trish) Simner, PhD, D(ABMM)
Director of Medical Bacteriology and Parasitology Laboratories
Associate Professor of Pathology
Johns Hopkins School of Medicine
Baltimore, MD

Dr. Simner discloses the following:
Consultant: Accelerate Diagnostics, CosmosID, OpGen Inc., and Roche Diagnostics
Research Grants: Accelerate Diagnostics, Affinity Biosensors, Check-Points BV, Hardy Diagnostics, and OpGen Inc.

Accredited Provider Disclosure

ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

Credit

0.50

Type

AMA PRA Category 1 Credit(s)TM

Accreditation Statement



The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation Statement

The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 0.50 AMA PRA Category 1 CreditsTM  .  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit

0.50

Type

CE for Pharmacists

Accreditation Statement

The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Designation Statement

This activity has been approved for 0.50 contact hours.
ACPE Universal Activity Number: 0396-0000-19-006-H01-P
Activity Type: Knowledge

Credit

0.10

Type

CE Credit

Accreditation Statement


The Academy for Continued Healthcare Learning (ACHL) has been accredited as an Authorized Provider by the International Association for Continuing Education and Training (IACET). In obtaining this accreditation, the ACHL has demonstrated that it complies with the ANSI/IACET Standard which is recognized internationally as a standard of good practice. As a result of the Authorized Provider status, ACHL is authorized to offer IACET CEUs for programs that qualify under the ANSI/IACET Standard.

Designation Statement

ACHL is authorized by IACET to offer 0.10 CEU for this program.

IACET CEUs are accepted by the American Nurses Association. Contact your licensing agency for details.

Disclosure of Unlabeled Use

Novel antibiotics and available antibiotics under investigation for use in different types of serious infections.

Disclaimer

The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.

This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support, as well as the ACPE Accreditation Standards for Continuing Pharmacy Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.

Instructions

This activity will take approximately 30 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 66% must be achieved on the posttest. A certificate will be immediately available and emailed, please be sure to check spam/junk mailbox. There is no fee to participate in the activity or for the generation of the certificate. Your certificate will be saved on the ACHL website and will not be available in your myCME CME History.

CPE credit will be submitted to CPE Monitor® on the first day of each month.Your certificate will be saved on the ACHL website and will not be available in your myCME CME History.

For questions, please contact Katlyn Cooper at kcooper@achlcme.org.

Privacy Policy

Add to Queue


Related to this activity

Refractory Outpatient HFrEF Patient Case Study

Refractory Outpatient HFrEF

CME 0.50 Credits